Half-Life (Normalesrd) Hours
63-69/No data
Plasma Protein Binding %
40
Volume Of Distribution L/Kg
0.87-1.45
Dose For Normal Renal Function
100 mg qd
Second Dose
Second Dose: 100-300 mg bid qd
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
75-100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50-75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data, [D]
References
Ieiri I, Morioka T, Kim S, Nishio S, Fukui M, Higuchi S. Pharmacokinetic study of zonisamide in patients undergoing brain surgery. J Pharm Pharmacol. 1996; 48: 1270-5.[PMID: 9004190] / Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998; 38: 166-71. [PMID: 9549648] / Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther. 1995; 67: 351-84. [PMID: 8577822]
Toxicity Notes
Zonisamide should not be used in patients with renal failure (estimated GFR <50 mL/min) because there has been insufficient experience concerning drug dosing and toxicity. The initial dose should be 100 mg daily. After 2 weeks, the dose may be increased to 200 mg/day for at least 2 weeks. It can be increased to 300 mg/day and 400 mg/day, with the dose stable for at least 2 weeks to achieve steady-state at each level. Evidence from controlled trials suggests that doses of 100-600 mg/day are effective for normal renal function. Dose recommendations for renal impairment based on clearance ratios.